Neurology Central

AAN 2018: Novel therapy for ‘difficult-to-treat’ migraines revealed

According to a preliminary Phase IIIB LIBERTY trial presented at the American Academy of Neurology’s 70th Annual Meeting (April 21–27, CA, USA), researchers have disclosed that a monoclonal antibody – termed erenumab – could prevent difficult-to-treat migraines in individuals who have tried unsuccessfully to prevent their migraines with other treatments.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.